Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | KDR | P35968 | 8/20 | 0.56 |
| ▸ | FGFR3 | P22607 | 8/20 | 0.56 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.53 |
| ▸ | LYN | P07948 | 1/20 | 0.53 |
| ▸ | FYN | P06241 | 3/20 | 0.47 |
| ▸ | DYRK3 | O43781 | 3/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.47 |
| ▸ | DYRK2 | Q92630 | 3/20 | 0.47 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.47 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.46 |
| ▸ | CDK2 | P24941 | 2/20 | 0.46 |
| ▸ | CDK9 | P50750 | 2/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.46 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | CSF1R | P07333 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3923867 | 0.85 | HPGD (0.70) | HPGDKDRFGFR3RIPK2LYN | |
| SCHEMBL3925188 | 0.84 | HPGD (0.69) | HPGDKDRFGFR3RIPK2LYN | |
| SCHEMBL3925199 | 0.84 | HPGD (0.69) | HPGDKDRFGFR3RIPK2LYN | |
| SCHEMBL3925191 | 0.83 | HPGD (0.67) | HPGDKDRFGFR3RIPK2LYN | |
| SCHEMBL5260603 | 0.83 | FGFR3 (0.54) | HPGDKDRFGFR3FYNDYRK3 | |
| SCHEMBL31096093 | 0.82 | KDR (0.54) | HPGDKDRFGFR3RIPK2FYN | |
| SCHEMBL25250638 | 0.79 | EGLN2 (0.59) | KDRFGFR3RIPK2FLT3 | |
| SCHEMBL23673366 | 0.79 | FGFR3 (0.45) | HPGDKDRFGFR3RIPK2 | |
| SCHEMBL23675321 | 0.79 | HPGD (1.00) | HPGDKDRFGFR3 | |
| SCHEMBL13336709 | 0.78 | KDR (0.65) | KDRFGFR3FYNFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11345702-B1 | PGDH inhibitors and methods of making and using | MYOFORTE THERAPEUTICS, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| WO-2022082009-A1 | INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF | EPIRIUM BIO INC. (US) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345702-B1 | PGDH inhibitors and methods of making and using | HPGD, HPGDS, PTGS1 | HPGD 1/4885KDR 4568/4885FGFR3 4025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.